Page last updated: 2024-08-25

picropodophyllin and Carcinoma, Squamous Cell

picropodophyllin has been researched along with Carcinoma, Squamous Cell in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dyrager, C; Fryknäs, M; Gullbo, J; Lennartsson, J; Sooman, L; Wickström, M; Wu, X	1
Bergqvist, M; Bergström, S; Brandén, E; Ekman, S; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Koyi, H; Larsson, O; Lundström, KL; Ringbom, M	1
Cherpelis, B; Rudnick, EW; Thareja, S	1
Clayburgh, DR; Gross, ND; Koide, J; Proby, C; Wong, MH	1

Reviews

1 review(s) available for picropodophyllin and Carcinoma, Squamous Cell

Article	Year
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. International journal of dermatology, 2016, Volume: 55, Issue:3 Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden	2016

Article

Year

Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.

International journal of dermatology, 2016, Volume: 55, Issue:3

Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden

2016

Trials

1 trial(s) available for picropodophyllin and Carcinoma, Squamous Cell

Article	Year
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Podophyllotoxin; Prognosis; Receptor, IGF Type 1; Tissue Distribution	2015

Article

Year

A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.

Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:4

Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Podophyllotoxin; Prognosis; Receptor, IGF Type 1; Tissue Distribution

2015

Other Studies

2 other study(ies) available for picropodophyllin and Carcinoma, Squamous Cell

Article	Year
Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitro. Molecular cancer therapeutics, 2013, Volume: 12, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Humans; Microtubules; Phosphorylation; Podophyllotoxin; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Tubulin Modulators	2013
Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality. Head & neck, 2013, Volume: 35, Issue:1 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2013

Article

Year

Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitro.

Molecular cancer therapeutics, 2013, Volume: 12, Issue:8

Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Humans; Microtubules; Phosphorylation; Podophyllotoxin; Protein Kinase Inhibitors; Receptor, IGF Type 1; Signal Transduction; Tubulin Modulators

2013

Effects of epidermal growth factor receptor and insulin-like growth factor 1 receptor inhibition on proliferation and intracellular signaling in cutaneous SCCHN: potential for dual inhibition as a therapeutic modality.

Head & neck, 2013, Volume: 35, Issue:1

Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor Binding Protein 1; Podophyllotoxin; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck

2013